Breast Cancer Innovator Atossa Genetics Has Added Alchem Laboratories As Second Manufacturer to Supply “Increasing Need” Of Endoxifen
Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS) a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, announced this week that is has added Alchem Laboratories as a U.S. contract manufacturer to supply Endoxifen. Subject to successful bioequivalence and other testing, the material will be used to produce both oral and topical drug product presentations.
Alchem Laboratories is located in Gainesville, Florida. It has supplied APIs for 16 active clinical studies, 13 of which were led by the National Cancer Institute (NCI) and that Alchem has been supporting through multiple R&D contracts for over fifteen years. In 2018, Alchem added oral and injectable products to its topical product manufacturing capabilities in its GMP clinical manufacturing facility expansion.
Alchem provides qualified infrastructure and trained personnel for all stages of drug development including design and synthesis of novel compounds, synthesis of analogs of lead compounds, process development and optimization, analytical method development and validation, stability studies for drugs and intermediates, cGMP manufacturing of APIs and products for clinical studies, and documentation for all stages of drug development. Its partners and collaborators include the NCI, part of the National Institutes of Health (NIH), the National Institute of Standards and Technology (NIST), the U.S. Army Medical Research Acquisition Activity (USAMRAA), the U.S. Department of Agriculture (USDA), the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (ICP), Gemphire Therapeutics, Inc., Cerenis Therapeutics Holding SA, Brickell Biotech, Inc., FLUCEL LLC, Nanopharmaceutics, MRIGlobal, Pace Analytical Labs, Southern Research, and the University of Florida UF|INNOVATE – Sid Martin Biotech.
Dr. Steven Quay, Ph.D., MD, President and CEO of Atossa. stated, “Our needs for the ongoing clinical supply of Endoxifen are dramatically increasing as we advance our clinical studies. As a second Endoxifen manufacturer, Alchem will begin supplying Endoxifen for one or more of our studies slated for later this year. They will be an excellent partner, with their experience and capabilities, to ensure we are poised to move our development programs forward quickly, particularly in the U.S.”
Here is a list of Atossa’s clinical programs that are using its proprietary Endoxifen include:
- Phase 2 study to determine if oral Endoxifen reduces tumor activity in early stage breast cancer patients in the “window of opportunity” between diagnosis of breast cancer and surgery (now open for enrollment in Australia)
- Phase 2 study to determine if topical Endoxifen reduces mammographic breast density (now open for enrollment in Sweden)
- Phase 1 study of topical Endoxifen in men (enrollment and dosing complete; results to be announced this quarter)
- Phase 2 study of topical Endoxifen to treat gynecomastia in men being treated for prostate cancer (study targeted to open in Q4 2018)
- Phase 2 study of oral Endoxifen for patients who are “refractory” to Tamoxifen (study targeted to open in 2H 2018)
Maxim Group’s Biotechnology Analyst Jason McCarthy issued an update report recently and maintained his “Buy rating” and his $10/price target.